Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1682

Feb 1, 2020

Coronavirus Research Is Moving at Top Speed—With a Catch

Posted by in category: biotech/medical

Scientists are posting their papers on the China outbreak as fast as they can write them, skipping traditional journals.

Feb 1, 2020

CAREFUL! Cybersecurity experts warn of viruses disguised as coronavirus information

Posted by in categories: biotech/medical, cybercrime/malcode

Cybersecurity experts are issuing a warning surrounding threats of computer viruses posing online as files about the deadly coronavirus outbreak.

“It’s getting their attention, because everyone’s been in tune, around the world, on this virus,” Raleigh cybersecurity expert Giovanni Masucci said to our NBC affiliate WECT.

Feb 1, 2020

MRI scans delve into dog-like complexity of squid brains

Posted by in categories: biotech/medical, neuroscience

New research led by Wen-Sung Chung and Justin Marshall of the University of Queensland is shedding new light on the complexity of squid brains. Using MRI scanning to examine the brain of the of the reef squid Sepioteuthis lessoniana, the researchers have produced a new map of neural connections that improves our understanding of their behavior.

The cephalopods are widely recognized as the most intelligent of mollusks, but how do they rate when they are competing against something other than clams? Cephalopods show all sorts of complex behavior, like being able to recognize patterns, solve problems, communicate through signals, and camouflage themselves in different textures and colors, despite being colorblind.

“We can see that a lot of neural circuits are dedicated to camouflage and visual communication,” says Chung. “Giving the squid a unique ability to evade predators, hunt and conspecific communicate with dynamic color change.”

Feb 1, 2020

Setting the agenda for social science research on the human microbiome

Posted by in categories: biotech/medical, governance, health, policy, science

The human microbiome is an important emergent area of cross, multi and transdisciplinary study. The complexity of this topic leads to conflicting narratives and regulatory challenges. It raises questions about the benefits of its commercialisation and drives debates about alternative models for engaging with its publics, patients and other potential beneficiaries. The social sciences and the humanities have begun to explore the microbiome as an object of empirical study and as an opportunity for theoretical innovation. They can play an important role in facilitating the development of research that is socially relevant, that incorporates cultural norms and expectations around microbes and that investigates how social and biological lives intersect. This is a propitious moment to establish lines of collaboration in the study of the microbiome that incorporate the concerns and capabilities of the social sciences and the humanities together with those of the natural sciences and relevant stakeholders outside academia. This paper presents an agenda for the engagement of the social sciences with microbiome research and its implications for public policy and social change. Our methods were informed by existing multidisciplinary science-policy agenda-setting exercises. We recruited 36 academics and stakeholders and asked them to produce a list of important questions about the microbiome that were in need of further social science research. We refined this initial list into an agenda of 32 questions and organised them into eight themes that both complement and extend existing research trajectories. This agenda was further developed through a structured workshop where 21 of our participants refined the agenda and reflected on the challenges and the limitations of the exercise itself. The agenda identifies the need for research that addresses the implications of the human microbiome for human health, public health, public and private sector research and notions of self and identity. It also suggests new lines of research sensitive to the complexity and heterogeneity of human–microbiome relations, and how these intersect with questions of environmental governance, social and spatial inequality and public engagement with science.

Feb 1, 2020

CDC: Flu deaths reach 10K this season

Posted by in category: biotech/medical

Stay aware.


The CDC estimates that so far this season there have been at least 19 million flu illnesses and 180,000 hospitalizations.

Flu was widespread in Puerto Rico and 49 states. In Hawaii, the District of Columbia and the U.S. Virgin Islands, the outbreaks were less active.

Continue reading “CDC: Flu deaths reach 10K this season” »

Feb 1, 2020

Mining coronavirus genomes for clues to the outbreak’s origins

Posted by in category: biotech/medical

Theories abound about how the virus that’s now rampant in China made its way from bats (almost certainly) to humans.

Feb 1, 2020

MIT discovery: A drug to cure nearly any virus

Posted by in category: biotech/medical

Circa 2011


In tests, the new drug was effective against rhinoviruses that cause the common cold, the swine flu virus H1N1, a stomach virus, a polio virus and dengue fever.

Feb 1, 2020

Xenobots Have Heart (Cells) — DTNS 3700

Posted by in categories: biotech/medical, robotics/AI

Scientists from Tufts University, the University of Vermont, and the Wyss Institute at Harvard published early research in Proceedings of the National Academy of Sciences about robots made from heart and skin cells derived from frog embryo stem cells that they call xenobots. What does this mean for robotics and what are the ethical issues at play?

Starring tom merritt, sarah lane, len peralta, roger chang, annalee newitz.

Continue reading “Xenobots Have Heart (Cells) — DTNS 3700” »

Feb 1, 2020

Coronavirus Outbreak Emerged from Bats, Genomic Findings Suggest

Posted by in category: biotech/medical

Sequencing multiple nCoV-2019 strains from patients, two teams from China has solved one piece of the outbreak puzzle—where the virus originated.

Feb 1, 2020

Coronavirus update Vaccine expected in Phase 1 trial within months WHO to reconvene on Thursday

Posted by in category: biotech/medical

A vaccine designed to combat severe acute respiratory syndrome (SARS) and technological advances in vaccine platforms are likely to quicken the time it will take to develop a vaccine for the novel coronavirus that has killed at least 132 people and sickened nearly 6,000 others.

“I’m reasonably confident that within three months or less we’ll be in a Phase 1 trial” for a coronavirus vaccine, which would be record speed for this type of trial, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said during a Tuesday video interview with the medical journal JAMA. It took 3.2 months to get a Zika vaccine into trials, he added.